A critical assessment of oxaprozin clinical profile in rheumatic diseases

Inflammopharmacology

Volumn 10, Issue 3, 2002, Pages 241-284

  Kean, Walter F ^a   Kean, Robert ^a   Buchanan, W Watson ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Efficacy; Meta analysis; Osteoarthritis; clinical trials; Oxaprozin; Rheumatoid arthritis; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; IBUPROFEN; INDOMETACIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PLACEBO; PROPIONIC ACID DERIVATIVE; ZOMEPIRAC;

ANKYLOSING SPONDYLITIS; BURSITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATORY DISEASE; MYALGIA; NAUSEA; OSTEOARTHRITIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; TENDINITIS; TOOTH PAIN; VOMITING;

EID: 0036957812     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856002321168213     Document Type: Conference Paper

References (63)

1. Appelrouth, D. J., Chodock, A. L., Miller, J. L. and Powell, W. R. (1986). A comparison of single daily doses of oxaprozin with multiple daily doses of ibuprofen for the treatment of Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism 15 (Suppl. 2), 54-58.
2. Barber, J. V., Collins, R. L., Kitridou, R. C., Lehman, D. H., Wenger, M. E. and Wold, R. T. (1986). The efficacy and safety of single daily doses of oxaproxin in the treatment of Rheumatoid Arthritis: a comparison with aspirin, Seminars in Arthritis and Rheumatism 15 (3), Suppl. 2, 47-53.
3. Bevilacqua, M. (2002). Effects of oxaprozin and of other 2-arylpropionic acid derivatives on Nuclear Factor κB (NF-κB) activation, Inflammopharmacology 10, 173-183.
4. Blau, R. A., Boyles, P. W., Brame, C. L., Bress, N. M., Clarke, J. P., Conner, S. K., Cummings, N., Krauster, R. E., Poiley, J. E., Roth, S. H. and Spindler, J. S. (1983). Comparison of the efficacy and safety of oxaprozin (600 mg b.i.d.) versus ibuprofen (300 mg q.i.d.) in the treatment of patients with active Rheumatoid Arthritis, Internal report (Ref: Protocol B).
5. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos, Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K. and Schnitzer, T. J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N. Engl. J. Med. 343, 1520-1528.
6. Bonner, W. M., Briney, W. G., Heller, M., Kaplan, S. B., Katz, W. A., Lages, W. L., Leroy, E. C., Martin, P. H., Olson, E. G., Samuels, B. S., Simson, J. and Vreede, P. D. (1983). Comparison of the efficacy and safety of oxaprozin (600 mg b.i.d.) versus aspirin (975 mg q.i.d.) in the treatment of patients with active rheumatoid arthritis, Internal report (Ref: Protocol C).
7. Bono, R. F., Finkel, S., Goodman, H. F., Hanna, C. B., Rabinowitz, S. R. and Sharon, E. (1983). Comparison the efficacy and safety of oxaprozin (1200 mg o.d.) versus phenylbutazone (100 mg q.i.d.) versus placebo in the treatment of patients with acute tendonitis and bursitis, Internal report (Ref: Protocol T1).
8. Brandon, M. L. and Brobyn, R. D. (1983). Six week comparison of the efficacy and safety of oxaprozin (600 mg b.i.d.) vs aspirin in the treatment of patients with osteoarthritis, Internal report (Ref: Protocol 01).
9. Brooks, P. and Brooks, A. (1984). Comparison of the efficacy and safety of oxaprozin (1200 mg q.d.) versus naproxen (750 mg per day) in the treatment of patients with rheumatoid arthritis, Internal report (Ref: GMR 10637).
10. Cervoni, W. A., Heights, C. and Wilkens, R. (1983). Two-week double-blind crossover study of oxaprozin (300 and 600 mg b.i.d.) vs. placebo in patients with Rheumatoid Arthritis, Internal report (Ref: Protocol 912).
11. Couchman, K. G. and Sheppeard, H. (1986). The effect of anti-rheumatic drugs on factors from porcine synovium inducing chondrocyte mediated cartilage degradation, Agents Actions 19, 116-122.
12. Cooper, S. A., Itkyn, A. and Zweig, B. (1992). Comparison of oxaprozin, aspirin, and placebo in a dental impaction pain model, Adv. Ther. 9, 184-191.
13. Dallegri, F. and Ottonello, L. (2002). Pharmacological implications in the switch from acute to chronic inflammation, Inflammopharmacology 10, 159-171.
14. Davies, N. M. (1998). Clinical pharmacokinetics of oxaprozin, Clinical Pharm 35, 42-36.
15. Dedhiya, S. D., Zhao, S. Z., Bocanegra, T. S., Kuss, M. E., Rush, S. M., Talwalker, S. S. and Johnson, K. E. (1998). Effect of health related quality of life among patients with osteoarthritis of the knee treated with oxaprozin potassium, J. Rheumatol. 25 (Suppl. 52), 5.
16. DerSimonian, R. and Laird, N. (1986). Meta-analysis in clinical trials, Control Clin. Trials 7, 177-188.
17. Digby, J. W., Khanna, V. N., Reynolds, W. J. and Woodbury, J. F. L. (1983). Comparison of the efficacy and safety of oxaprozin (1200 mg o.d.) versus aspirin (975 mg q.i.d.) in the treatment of patients with active rheumatoid arthritis, Internal report (Ref: Protocol 93802).
18. Flood, J. (1993). Effectiveness and safety of oxaprozin versus aspirin for Rheumatoid Arthritis, J. Musculoskel. Med. 10 (Suppl. 3), 38-44.
19. Forbes, J. A. and Beaver, W. T. (1994). A 12-h evaluation of oxaprozin and aspirin in post-operative oral surgery pain, Clin. Pharmacol. Ther. 55, 127.
20. Ginsberg, F. and Famaey, J. P. (1984). A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of Osteoarthritis, Curr. Med. Res. Opin. 8, 689-695.
21. Ginsberg, F. and Famaey, J. P. (1990). Double blind six-month comparative study of the efficacy and tolerance of oxaprozin and diclofenac in the symptomatic treatment of osteoarthritis of the hip or knee joint, Internal report (Ref: GMR 17972).
22. Hatoum, H. T., Ware, J. E., Keller, S. D., Xiaodong, K., Kuss, M. E. and Bocanegra, T. S. (1996). Effect of oxaprozin and nabumetone on health-related quality of life of patients with Osteoarthritis of the knee, Arthritis Rheumatism 39, S225.
23. Hubsher, J. A., Ballard, I. M., Walker, B. R. and Gold, J. A. (1979). A multicentre double-blind comparison of oxaprozin aspirin therapy on Rheumatoid Arthritis, J. Int. Med. Res. 7, 69-76.
24. Hubsher, J. A., Bono, R. F., Finkel, S. and Hanne, C. B. (1982). Comparison of the efficacy and safety of oxaprozin and phenylbutazone versus placebo in the treatment of patients with acute tendinitis/bursitis, Clin. Res. 30, 806A.
25. Jadad, A. R., Carroll, D., Moore, A. and McQuay, H. (1996). Developing a database of published reports of randomised clinical trials in pain research, Pain 66, 239-246.
26. Jasper, R. D., Mehlisch, D. R., Bocanegra, T., Kuss, M., Canju, J. and Brown, J. (1997). Onset and duration of analgesia of oxaprozin potassium, oxaprozin acid, and ibuprofen in post-operative dental pain, Clin. Pharmacol. Ther. 61, 199.
27. Juni, P., Rutjes, A. W. and Dieppe, P. A. (2002). Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?, Br. Med. J. 324 (7349), 128.
28. Kaplan, D. and O'Brien, W. (1990). Nine-week double-blind crossover study of oxaprozin (300 mg b.i.d.) vs. aspirin in the treatment of patients with active Rheumatoid Arthritis, Internal report (Ref: Protocol 906).
29. Kaplan, D., Kaplan, S. B. and O'Brien, W. M. (1983). Two-week double-blind crossover study of oxaprozin (20 mg/kg per day) vs. placebo in the treatment of patients with active Rheumatoid Arthritis, Internal report (Ref: Protocol 913).
30. Kaplan, S. and Levy, J. (1990). Nine-week double-blind crossover study of oxaprozin (600 mg b.i.d.) vs. aspirin in the treatment of patients with active Rheumatoid Arthritis, Internal report (Ref: Protocol 907).
31. Karbowsky, A., Schwitalle, M. and Eckardt, A. (1998a). Therapie der Rheumatoiden Arthritis mit nichtsteroidalen Antiphlogistika: oxaprozin versus diclofenac, Akt. Rheumatol. 23, 11-15.
32. Karbowsky, A., Schwitalle, M. and Eckardt, A. (1998b). Oxaprozin versus diclofenac retard for the treatment of active Osteoarthrosis, Z. Rheumatol. 57, 108-113.
33. Kaye, B. R. (1993). Evaluation of the efficacy of oxaprozin, a new once-a-day NSAID: A comparative clinical trial with piroxicam in patients with osteoarthritis of the hip or knee joint, Drug Ther. 23 (3S), 17-20.
34. 2 production from platelets, J. Pharm. Sci. 78, 324-328.
35. Kolodny, L., Klipper, A. R., Harris, B. K., Howard, F. M., Kahn, C. B., Riskin, W. G., Weaver, A. L. and Willkens, R. F. (1986). The Efficacy and safety of Single Daily Doses of Oxaprozin in the Treatment of Osteoarthritis: A Comparison with Aspirin, Seminars in Arthritis and Rheumatism 15 (Suppl. 2), 72-79.
36. Kurowski, M. and Thabe, H. (1989). The transsynovial distribution of oxaprozin, Agents Actions 27, 458-460.
37. Liberti, L. E. (1983). Comparison of the efficacy and safety of oxaprozin (1200-1800 mg/day) versus indomethacin (50-200 mg/day) in the treatment of patients with active Ankylosing Spondylitis, Internal report (Ref: GMR 10362).
38. Liberti, L. E. (1984). Comparison of the efficacy and safety of oxaprozin (1200 mg o.d.) vs. zomepirac (100 mg q.i.d.) in the treatment of patients with active Osteoarthritis, Internal report (Ref: GMR 10570).
39. Liberti, L. E. and Hubsher, J. A. (1984). Comparison of the efficacy and safety of oxaprozin 1200 mg and piroxicam 20 mg given once daily in the treatment of patients with Osteoarthritis, Internal report (Ref: GMR 11104).
40. Makarowski, W., Weaver, A., Rubin, B., Caldwell, J., Mcmahon, L. D., Noveck, R. J., Offenberg, H., Sack, M., Sikes, D., Trapp, R., Rush, S. and Kuss, M. (1996). The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with Osteoarthritis of the knee, Clin. Ther. 18, 114-124.
41. McCloud, S. J. (1988a). A comparative study of the effects of oxaprozin and piroxicam in patients with Osteoarthritis of the hip or knee joint, Internal report (Ref: GMR 15442).
42. McCloud, S. J. (1988b). A double blind, parallel group, comparative study of the efficacy and safety profile of oxaprozin and piroxicam in patients with Osteoarthritis of the hip or knee joint, Internal report (Ref: GMR 15532).
43. Muller-Fassbender, H. (1990). A double blind parallel group comparative study of the efficacy and tolerance of oxaprozin and diclofenac in the symptomatic treatment of Rheumatoid Arthritis, Internal report (Ref: GMR 18279).
44. Osborn, T. G. (1993). Oxaprozin compared with piroxicam for Osteoarthritis, J. Musculoskeletal Med. 10 (Suppl. 3), 33-37.
45. Poiley, J. E., Spindler, J. S., Clarke, J. P. and Brame, C. L. (1986). Nonsteroidal antiinflamatory drug therapy in Rheumatoid Arthritis: A comparison of oxaprozin and ibuprofen, Semin. Arthritis Rheum. 15 (Suppl. 2), 59-65.
46. Rainsford, K. D., Omar, H., Ashraf, A., Hewson, A. T., Bunning, R. A. D. and Rishiraj, R. (2002). Recent Pharmacodynamic and Pharmacokinetic Findings on Oxaprozin, Inflamopharmacology 10, 185-239.
47. Schattenkirchner, M. (1988). Double-blind comparison of the efficacy and tolerance of oxaprozin and placebo in the treatment of Rheumatoid Arthritis, Internal report (Ref: GMR 15641).
48. Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, the CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Safety Study, J. Am. Med. Ass. 284, 1247-1255.
49. Simon, L. S., Smolen, J. S. and Abramson, S. B. (2002). Controversies in COX-2 selective inhibition, J. Rheumatol. 29, 1501-1510.
50. Skrifvars, B. (1986). Oxaprozin once a day (1200 mg) compared to naproxen twice a day (1000 mg/day) in the symptomatic treatment of Rheumatoid Arthritis over six months, Internal report (Ref: GMR 12903).
51. Spruell, W. H., Sharon, E. and Collins, R. L. (1984). Comparison of the efficacy and safety of oxaprozin 1200 mg versus piroxicam 20 mg given once daily in the treatment of patients with Rheumatoid Arthritis, Internal report (Ref: GMR 10972).
52. Strand, V. and Hochberg, M. (2002). The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors, Arthritis Rheum. 47, 349-355.
53. Tengler, D. (1990a). Double blind parallel comparative study of the short-term efficacy and tolerance of oxaprozin and diclofenac retard in the symptomatic treatment of Osteoarthritis of the hip or knee joint, Internal report (Ref: GMR 17971).
54. Tengler, D. (1990b). Double blind parallel comparative study of the efficacy and tolerance of oxaprozin and piroxicam in the symptomatic treatment of Osteoarthritis of the hip and/or knee joint, Internal report (Ref: GMR 18139).
55. Tisscher, J. R. (1988). A placebo controlled study of the absolute efficacy and short-term tolerance of oxaprozin in the symptomatic treatment of Rheumatoid Arthritis, Internal report (Ref: GMR 15563).
56. Todd, P. A. and Brogden, R. N. (1986). Oxaprozin: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs 32, 291-312.
57. Vaz, A. L. (1984). Comparison of the efficacy and safety of oxaprozin 1200 mg q.d. versus indocin retard (150 mg per day) in the treatment of patients with active Rheumatoid Arthritis, Internal report (Ref: GMR 10823).
58. Vreede, P. D., Harper, F. E. and Sheldon, W. B. (1986). Use of oxaprozin in the treatment of aspirin failures in Rheumatoid Arthritis, Semin. Arthritis Rheum. 15 (Suppl. 2), 66-71.
59. Waxman, J. (1993). The efficacy and safety of oxaprozin versus piroxicam: Pooled results of doubleblind trials in Osteoarthritis, Drug Ther. 23 (3S), 13-16.
60. Weaver, A., Bernard, R., Caldwell, J., McMahon, F. G., Lee, D., Makarowski, W., Offenberg, H., Sack, M., Sikes, D., Trapp, R., Rush, S., Kuss, M., Ganju, J. and Bocanegra, T. S. (1995). Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with Osteoarthritis of the knee, Clin. Ther. 17, 735-745.
61. Winter, L. and Post, A. (1983). Double-blind comparison of single oral doses of oxaprozin, aspirin and placebo for relief of post-operative oral surgery pain, J. Int. Med. Res. 11, 308-314.
62. Zhao, S. Z., Dedhiya, S. D., Bocanegra, T. S., Fort, J. G., Kuss, M. E. and Rush, S. M. (1999). Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee, Clin. Ther. 21, 205-217.
63. Zinny, M. A. (1993). The effects of age and sex on oxaprozin single-dose and mutliple-dose pharmacokinetics, Drug Ther. 23 (S), 37-45.